Drug-drug interactions: Implications for anticoagulation, with focus in patients with cancer
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Drug-drug interactions: Implications for anticoagulation, with focus in patients with cancer
Authors
Keywords
Drug-drug interaction, Cancer-associated thrombosis, Venous thromboembolism, Anticoagulation, Malignancy
Journal
THROMBOSIS RESEARCH
Volume 213, Issue -, Pages S66-S71
Publisher
Elsevier BV
Online
2022-05-26
DOI
10.1016/j.thromres.2021.11.026
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer
- (2021) Gary H. Lyman et al. Blood Advances
- 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation
- (2021) Jan Steffel et al. EUROPACE
- Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism
- (2021) Melina Verso et al. EUROPEAN JOURNAL OF CANCER
- Correction to: Effect of Enzyme‑Inducing Antiseizure Medications on the Risk of Sub‑Therapeutic Concentrations of Direct Oral Anticoagulants: A Retrospective Cohort Study
- (2021) Amichai Perlman et al. CNS DRUGS
- Characteristics and outcomes of patients on concurrent direct oral anticoagulants and targeted anticancer therapies—TacDOAC registry: Communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy
- (2021) Tzu‐Fei Wang et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Prospective evaluation of drug–drug interactions in ambulatory cancer patients initiated on prophylactic anticoagulation
- (2020) Hank K Ng et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Incidence and consequences of resuming oral anticoagulant therapy following hematuria and risks of ischemic stroke and major bleeding in patients with atrial fibrillation
- (2020) Chun-Li Wang et al. JOURNAL OF THROMBOSIS AND THROMBOLYSIS
- Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer
- (2020) Giancarlo Agnelli et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE
- (2020) Jeffrey I. Weitz et al. JOURNAL OF THROMBOSIS AND THROMBOLYSIS
- Drug-drug interactions affecting drug levels of direct oral anticoagulants in the real world: A systematic review
- (2020) Allen Li et al. THROMBOSIS RESEARCH
- Risk of Hospitalization With Hemorrhage Among Older Adults Taking Clarithromycin vs Azithromycin and Direct Oral Anticoagulants
- (2020) Kevin Hill et al. JAMA Internal Medicine
- Bleeding and thromboembolism due to drug-drug interactions with non-vitamin K antagonist oral anticoagulants—a Swedish, register-based cohort study in atrial fibrillation outpatients
- (2020) Johan Holm et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Increased bleeding risk associated with concurrent vascular endothelial growth factor receptor tyrosine kinase inhibitors and low‐molecular‐weight heparin
- (2020) Sandip H. Patel et al. CANCER
- Concomitant Use of Direct Oral Anticoagulants and Antiepileptic Drugs: A Prospective Cohort Study in Patients with Atrial Fibrillation
- (2020) Michela Giustozzi et al. CLINICAL DRUG INVESTIGATION
- Venous thromboembolism in cancer patients: a population-based cohort study
- (2020) F. I. Mulder et al. BLOOD
- Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer
- (2019) Alok A. Khorana et al. NEW ENGLAND JOURNAL OF MEDICINE
- The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH
- (2019) Tzu‐Fei Wang et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Impact of Polypharmacy and P-Glycoprotein- and CYP3A4-Modulating Drugs on Safety and Efficacy of Oral Anticoagulation Therapy in Patients with Atrial Fibrillation
- (2019) Ralf E. Harskamp et al. CARDIOVASCULAR DRUGS AND THERAPY
- Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update
- (2019) Nigel S. Key et al. JOURNAL OF CLINICAL ONCOLOGY
- Incidence of atrial fibrillation in different major cancer subtypes: a Nationwide population-based 12 year follow up study
- (2019) Christina Boegh Jakobsen et al. BMC CANCER
- Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial
- (2019) Robert D. McBane et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer
- (2019) Dominique Farge et al. LANCET ONCOLOGY
- Phase I Study of Dalteparin in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Carcinoma
- (2018) Madelon Q. Wentink et al. Clinical Genitourinary Cancer
- Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)
- (2018) Annie M. Young et al. JOURNAL OF CLINICAL ONCOLOGY
- Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH
- (2018) A. A. Khorana et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
- (2018) Gary E. Raskob et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anticancer Drug-Related Nonvalvular Atrial Fibrillation: Challenges in Management and Antithrombotic Strategies
- (2018) Maurizio Galderisi et al. SEMINARS IN THROMBOSIS AND HEMOSTASIS
- How I treat cancer-associated venous thromboembolism
- (2018) Noémie Kraaijpoel et al. BLOOD
- Apixaban to Prevent Venous Thromboembolism in Patients with Cancer
- (2018) Marc Carrier et al. NEW ENGLAND JOURNAL OF MEDICINE
- Drug-drug interactions of non-vitamin K oral anticoagulants
- (2016) Christos Voukalis et al. Expert Opinion on Drug Metabolism & Toxicology
- Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer
- (2015) Agnes Y. Y. Lee et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A pilot study on the impact of known drug-drug interactions in cancer patients
- (2015) Silvia Ussai et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial
- (2015) Christian T Ruff et al. LANCET
- Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions
- (2014) M. Levade et al. BLOOD
- Efficacy and Safety of Anticoagulant Therapy for the Treatment of Acute Cancer-Associated Thrombosis: A Systematic Review and Meta-Analysis
- (2014) Marc Carrier et al. THROMBOSIS RESEARCH
- The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients
- (2013) Paul A. Reilly et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
- (2013) Michael L. Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- New Oral Anticoagulants and the Cancer Patient
- (2013) N. J. Short et al. ONCOLOGIST
- Potential drug interactions in elderly cancer patients
- (2010) V. Girre et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now